Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Kerwin Medical Center outlines Alzheimer’s clinical trials, recruitment and barriers
Summary
Dr. Zed Shaw of Kerwin Medical Center told the Dallas Senior Affairs Commission about disease-modifying Alzheimer’s treatments, the role of clinical trials and local recruitment efforts; speakers discussed underrepresentation of Black participants and cost and access questions.
Dr. Zed Shaw, a clinician-researcher with Kerwin Medical Center, briefed the Dallas Senior Affairs Commission on recent advances in Alzheimer’s research, the role of clinical trials and how the center recruits trial participants.
Shaw told the commission that Alzheimer’s disease is the most common form of dementia and that age is the greatest risk factor. He described recent drug approvals as a shift from symptomatic therapy to treatments that target biologic changes in the brain, and he urged local participation in clinical trials to accelerate research and improve representation.
"In 2021 we had our first FDA-approved medication, aducanumab," Shaw said. "In 2024 we had lecanemab, and clinical trials show it slowed cognitive and functional decline by about 27 percent over the course of 18 months." He described both aducanumab and lecanemab as monoclonal…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
